Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06564103
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-08-19
Brief Title:
Stratification for F-L Therapy After LT
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Stratification for Efficacy of Adjuvant FOLFOX Plus Lenvatinib After Liver Transplantation for Hepatocellular Carcinoma in Recurrence Prevention
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Objective To stratify recipients who underwent adjuvant FOLFOX plus lenvatinib F-L therapy following liver transplantation LT for hepatocellular carcinoma and provide guidance for clinical adjuvant therapy
Methods Liver recipients in the Shulan Hangzhou Hospital from January 2017 to December 2021 including 106 in the F-L therapy group and 229 in the non-adjuvant N-A therapy group were included in the analysis A 11 propensity score matching PSM analysis was performed to minimize group imbalances Disease-free survival DFS and overall survival OS were compared among recipients Radiomics features that demonstrated predictive value for recurrence were employed either independently or in conjunction with prognostic clinical features to formulate predictive models The combined model was used to perform further subgroup analysis for recipients in the F-L therapy group
Methods Liver recipients in the Shulan Hangzhou Hospital from January 2017 to December 2021 including 106 in the F-L therapy group and 229 in the non-adjuvant N-A therapy group were included in the analysis A 11 propensity score matching PSM analysis was performed to minimize group imbalances Disease-free survival DFS and overall survival OS were compared among recipients Radiomics features that demonstrated predictive value for recurrence were employed either independently or in conjunction with prognostic clinical features to formulate predictive models The combined model was used to perform further subgroup analysis for recipients in the F-L therapy group
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None